Levodopa L-Veratrylglycine Impurity
✓
100% accuracy
of data
24/7 scientific
support
⬡
0% tolerance in
quality of product

Stock Locations

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

32161-30-1Levodopa L-Veratrylglycine Impurity

● In Stock

Catalogue No.:VL420012
CAS No.:32161-30-1
Mol. Formula:C11H15NO4
Mol. Weight:225.24 g/mol

Additional information on CAS 32161-30-1

Parent drug

Levodopa

IUPAC Name

(S)-3, 4-Dimethoxyphenylalanine

Pharmacopoeial synonyms

N/A

Other Synonyms

(2S)-2-amino-3-(3,4-dimethoxyphenyl)propanoic acid; L-Dimethoxyphenylalanine; Levodopa Dimethyl Ether; 3-Methoxy-O-methyl-L-tyrosine; β-(3,4-Dimethoxyphenyl)-L-alanine; 3, 4-Dimethoxy-L-phenylalanine

Smile

N[C@@H](CC1=CC=C(OC)C(OC)=C1)C(O)=O

InChI

InChI=1S/C11H15NO4/c1-15-9-4-3-7(6-10(9)16-2)5-8(12)11(13)14/h3-4,6,8H,5,12H2,1-2H3,(H,13,14)/t8-/m0/s1

Description

Levodopa L-Veratrylglycine Impurity is a meticulously characterized reference material that complies with rigorous regulatory requirements, including those defined by USP, EMA, JP, and BP. This product plays a crucial role in Abbreviated New Drug Applications (ANDA), New Drug Applications (NDA), and the commercial manufacturing of Levodopa. It is further supported by a detailed Structure Elucidation Report (SER), ensuring high accuracy and reliability across a broad range of analytical applications. Also known as Levodopa Dimethyl Ether, it is one of impurity present in Levodopa, Levodopa is a dopamine precursor used in the management of Parkinson’s disease, Levodopa metabolized to dopamine on side of the blood-brain barrier, so administered with a dopa decarboxylase inhibitor like carbidopa. which used to prevent metabolism until after it has crossed the blood-brain barrier. levodopa is metabolized to dopamine and used to treat symptoms of Parkinson’s.

References

Tambasco, N., Romoli, M., & Calabresi, P. (2018). Levodopa in Parkinson’s Disease: Current Status and Future Developments. Current Neuropharmacology, 16(8), 1239–1252. https://doi.org/10.2174/1570159×15666170510143821

Request a Quote

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
This field is hidden when viewing the form
Products quotation
Name
Url
 
This field is hidden when viewing the form
This field is hidden when viewing the form